PROK2 and neoplasm: In this study, we report our findings on the anti-tumor activity of a synthetic small molecule of PK2 antagonist, PKRA7 which can compete for the binding of PK2 to its receptors PKR1 and PKR2, consequently inhibiting the ability of PK2 to activate downstream pathways [Zhou, manuscript in preparation].